Isoray Medical passionately designs and develops innovative and personalized brachytherapy products that effectively treat many forms of cancer. We believe in pioneering solutions for life beyond your cancer.
Founded in 1998 to explore the medical use of Cesium 131 for the treatment of prostate cancer, Isoray’s low dose rate (LDR) brachytherapy product was cleared by the FDA for treatment of various cancers. Since the first patient was treated with Isoray’s Cesium product in October 2004, Isoray has provided products for over 10,000 patient treatments, including prostate cancer, brain, head & neck and gynecological tumors, and other isolated tumors and tumor beds.
Isoray has a dedicated team of employees who passionately work together to design, develop, produce and deliver products to address clinical needs and push the industry status quo with highly efficacious and patient-centric treatments.